|Day Low/High||1.70 / 1.82|
|52 Wk Low/High||1.42 / 8.12|
A sampling of stories published in the early morning hours Friday that you may have missed.
Ineptitude and mismanagement were the hallmarks of Robert Capetola, who has left as CEO of beleaguered drug company Discovery Labs.
Discovery Labs says president, founding CEO Robert Capetola resigns; Amick named interim CEO
This week, readers weigh in on Onyx Pharma's fund-raising, Savient's gout treatment and Spectrum's Fusilev.
Readers sound off on Discovery Labs, Micromet and BioDelivery.
Readers seek insight on Immunomedics, Discovery Labs and AMAG Pharmaceuticals.
Dendreon's Provenge data is certainly positive, but investors must consider regulatory and manufacturing concerns.
Discovery Laboratories receives another FDA request on the Surfaxin drug application
Market and economic turmoil and a new president cloud the forecast for the biotech sector, but investors can make some educated guesses.
Shares are down on a delay in the approval decision for an iron replacement drug, but the news could have been far worse.
The stock hasn't been this low since July 2007, but lung drug data could set it up for a rebound.
This biotech is a gamble, but the catalysts and timeline are established.
The Nasdaq and Amex biotechnology indices are up 1.2% and 0.7%, respectively.
If Roche is serious about buying the company, it will need to do much better than $89 a share.
The stock sinks after the company reveals it will not respond as swiftly as it thought to the FDA's concerns about Surfaxin.
The CEO last week disclosed a regulatory hiccup in its application for Cleviprex, months after the FDA first informed the company of a delay.
Shares fall 15% after the company's buyout by Microsoft falls apart.
The stock Monday regains some of its sharp Friday losses on the company's positive response to FDA delays. But is the reaction overly optimistic?
Discovery Labs falls on another regulatory delay for its Surflaxin.
Surfaxin receives an approvable letter, but the additional delays that accompany it send shares plummeting in premarket trading.
Shares soar 22% after the company announces in-line earnings.
BioMarin climbs higher after swinging to a profit and beating Wall Street estimates for the first quarter.
A regulatory decision on the lung treatment could come May 1, but even with approval the biotech will have to work for every bit of upside.
A lack of resources leads the agency to push back drug approval deadlines, adding murkiness to an already tricky sector.
Possis Medical soars after Bayer agrees to buy the company for $361 million.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.